How Tigilanol Tiglate (EBC-46) Works: PKC Activation and Three Pathways to Tumour Destruction
A deep-dive into how tigilanol tiglate (EBC-46) destroys tumours through three distinct pathways: PKC activation, rapid vascular disruption, and immune-mediated clearance — with full citations to the primary research.
How Tigilanol Tiglate Destroys Tumours: The Three-Phase Mechanism
EBC-46 (tigilanol tiglate) does not work like conventional chemotherapy. Rather than travelling through the bloodstream to attack dividing cells systemically, it operates through a highly localised, three-phase cascade when delivered directly into a tumour.[1]
Phase 1: PKC Activation and Vascular Disruption
Within minutes of injection, tigilanol tiglate activates protein kinase C (PKC) — a family of signalling enzymes that regulate cell growth, differentiation, and survival.[2]
This PKC activation triggers immediate disruption of the tumour's blood supply. The vasculature within the tumour haemorrhages, cutting off oxygen and nutrients. Tumour cells begin to die rapidly through a combination of ischaemia (oxygen deprivation) and direct cellular toxicity.
Phase 2: Acute Immune Response
As the tumour undergoes vascular collapse and cell death, it releases a flood of damage-associated molecular patterns (DAMPs) and tumour-associated antigens. This acts as a powerful immune alarm signal.
The innate immune system responds rapidly, recruiting neutrophils, macrophages, and natural killer (NK) cells to clear the dying tumour. A 2021 study confirmed this immune activation component plays a critical role in achieving complete responses.[3]
Phase 3: Adaptive Immune Memory
Peer-reviewed research has demonstrated that tigilanol tiglate treatment can stimulate abscopal-type effects — where the immune response generated at the tumour site trains the adaptive immune system to recognise and attack similar cancer cells elsewhere in the body.[4]
Why Localised Delivery Matters
Because EBC-46 is delivered intratumorally (injected directly into the tumour), systemic exposure is minimal. This is why the side effect profile of Stelfonta® in clinical and veterinary trials has been significantly more favourable than systemic chemotherapy agents.[5]
References
- Boyle GM et al. (2014). Intralesional injection of the novel PKC activator EBC-46. PLOS ONE. View source ↗
- Panizza BJ et al. (2019). Intralesional injection of tigilanol tiglate in head and neck cancers. ORL. View source ↗
- De Ridder TR et al. (2021). Randomized controlled trial of tigilanol tiglate for canine MCT. Journal of Veterinary Internal Medicine. View source ↗
- U.S. FDA (2020). FDA Approves Stelfonta. View source ↗
- ClinicalTrials.gov. Tigilanol tiglate studies. View source ↗
